• Explore /
  • Poster
  • / Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).

Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).

Abstract Poster

Authors

null

Suzanne George

Dana-Farber Cancer Institute, Boston, MA;

Suzanne George , George D. Demetri , Nick Lydon , Vivek Kadambi , Jessica Christo , Debbie Johnson , Patrick Schöffski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05489237

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS483)

DOI

10.1200/JCO.2023.41.4_suppl.TPS483

Abstract #

TPS483

Poster Bd #

N18

Abstract Disclosures

Similar Posters

First Author: David M Favara

First Author: Axel Le Cesne

First Author: William D. Tap

First Author: Steven Bialick